Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 14, 2022

Empagliflozin, Irrespective of Systolic BP, Improves Outcomes in Patients With HFpEF

European Heart Journal


Additional Info

European Heart Journal
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Eur Heart J 2022 Dec 07;[EPub Ahead of Print], M Böhm, S Anker, F Mahfoud, L Lauder, G Filippatos, JP Ferreira, SJ Pocock, M Brueckmann, I Saloustros, E Schüler, C Wanner, F Zannad, M Packer, J Butler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading